Efficacy and safety of R-GEMOX in relapsed or refractory diffuse large B-cell lymphoma: A single-center experience in Vietnam
Nội dung chính của bài viết
Tóm tắt
Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), yet a substantial proportion of patients experience relapse or refractory disease following initial therapy. Among various salvage regimens, R-GEMOX - comprising rituximab, gemcitabine, and oxaliplatin - has shown promising efficacy and a tolerable safety profile. This retrospective cohort study aimed to evaluate the treatment outcomes and adverse events associated with R-GEMOX in patients with relapsed or refractory CD20-positive DLBCL treated at Hanoi Oncology Hospital. A total of 39 patients who received at least four cycles of R-GEMOX between January 2018 and May 2024 were included. Treatment response was assessed using the Lugano 2014 criteria, and toxicities were graded per CTCAE v4.0. The median age of the cohort was 57.2 years old. The overall response rate (ORR) was 69.2%, including a complete response rate of 28.2% and a partial response rate of 41.0%. Stable disease and progressive disease were observed in 7.7% and 23.1% of patients, respectively. Grade 3-4 hematologic toxicities occurred in 30.8% of cases. Median progression-free survival (PFS) was 9.5 months, while median overall survival (OS) reached 15.7 months. These findings suggest that R-GEMOX is an effective and tolerable salvage regimen in the management of relapsed/refractory DLBCL, particularly for patients ineligible for high-dose chemotherapy or stem cell transplantation.
Chi tiết bài viết
Từ khóa
DLBCL, non-Hodgkin lymphoma, R-GEMOX, salvage chemotherapy, relapsed/refractory, Vietnam
Tài liệu tham khảo
2. Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80(8):1087-1097.
3. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
4. Perry AR, Goldstone AH. High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol Off J Eur Soc Med Oncol. 1998;9 Suppl 1:S9-14.
5. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002-1006.
6. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(31):3490-3496.
7. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(6):1169-1176.
8. López A, Gutiérrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008;80(2):127-132.
9. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(27):4184-4190.
10. Cazelles C, Belhadj K, Vellemans H, et al. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma. 2021;62(9):2161-2168.
11. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol Off J Eur Soc Med Oncol. 2007;18(8):1363-1368.
12. Van Heertum RL, Scarimbolo R, Wolodzko JG, et al. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719-1728.
13. Hou Y, Wang H qing, Ba Y. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma. Med Oncol Northwood Lond Engl. 2012;29(4):2409-2416.
14. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545.
15. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-654.